Amivantamab, a bispecific antibody to EGFR and mesenchymal epithelial transition factor (MET), was approved for marketing by the FDA in 2021 for the treatment of NSCLC (Syed, 2021). The gene discussed is MET; the disease is non-small cell lung carcinoma.